Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30043569 | 0.84 | POLB (0.41) | HCAR2ALDH1A1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL5294951 | 0.81 | RAB9A (0.40) | ALDH1A1MAPK1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL597064 | 0.79 | HCAR2 (0.57) | HCAR2ALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL29224469 | 0.79 | HCAR2 (0.44) | HCAR2ALDH1A1GAAPTPN1 | |
| SCHEMBL18973200 | 0.77 | HCAR2 (0.53) | HCAR2ALDH1A1POLBGAAPTPN1 | |
| SCHEMBL2530338 | 0.76 | HCAR2 (0.53) | HCAR2ALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL5297276 | 0.76 | VHL (0.42) | ALDH1A1MAPK1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL5287519 | 0.76 | RAB9A (0.34) | ALDH1A1MAPK1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL554742 | 0.75 | SMN1; SMN2 (0.57) | HCAR2ALDH1A1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL11899767 | 0.75 | HCAR2 (0.52) | HCAR2RAB9ASMN1; SMN2POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-11124502-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124502-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2012109100-A1 | SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202856-A1 | SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202856-A1 | SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202856-A1 | SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-09 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202856-A1 | SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | HCAR2 543/4885ALDH1A1 1861/4885MAPK1 2197/4885 |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885ALDH1A1 2776/4885MAPK1 1342/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | HCAR2 3637/4885ALDH1A1 2972/4885MAPK1 3183/4885 |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885ALDH1A1 2776/4885MAPK1 1342/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 658/4885ALDH1A1 2776/4885MAPK1 1342/4885 |
| US-11124502-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 658/4885ALDH1A1 2776/4885MAPK1 1342/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885ALDH1A1 2776/4885MAPK1 1342/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 658/4885ALDH1A1 2776/4885MAPK1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.